Ergothioneine for Cognition: Emerging Human Evidence, Null Results, and Limits

Bottom line: Ergothioneine has moved from an interesting dietary antioxidant story into early human intervention research. The signal is intriguing, but the larger randomized trial did not show a sustained benefit on its primary composite-memory outcome. That keeps the evidence firmly in the preliminary category.

Why ergothioneine is getting attention

Ergothioneine is a sulfur-containing compound obtained from the diet and concentrated in human tissues through a dedicated transporter, SLC22A4/OCTN1. Mushrooms are among its richest commonly discussed food sources.

Its chemistry makes it interesting for oxidative-stress and cellular-protection research, and observational studies have helped generate hypotheses around aging and neurological health.

Those observations are not the same as showing that taking ergothioneine improves cognition. Randomized supplementation trials matter much more for that question.

The one-year MCI pilot was positive—but tiny

A 2024 double-blind randomized placebo-controlled pilot enrolled just 19 adults aged 60 or older with mild cognitive impairment.[1]

Participants assigned to ergothioneine took a 25 mg capsule three times per week for one year. The investigators reported favorable changes in learning performance and stabilization of neurofilament light chain, a biomarker related to neuronal injury, without concerning changes in routine kidney, liver, or blood safety markers.[1]

That is worth following up. It is not a stable foundation for a broad claim because a 19-person pilot is highly vulnerable to chance, baseline imbalance, and exaggerated effect estimates.

The larger 2025 trial is more sobering

A 2025 randomized double-blind placebo-controlled trial enrolled 147 adults aged 55 to 79 with subjective memory complaints.[2] Participants received placebo, 10 mg/day, or 25 mg/day of ergothioneine for 16 weeks.

The primary outcome was change in a computerized composite-memory score.

The 25 mg group showed an early within-group memory improvement at week four, but that improvement was not sustained at week 16, and the trial did not establish a clear treatment effect on the primary composite-memory endpoint.[2]

Some secondary outcomes were more encouraging. The researchers reported dose-related signals in subjective prospective memory and sleep initiation, particularly at 25 mg. Those findings are useful for designing future trials, but secondary outcomes should not be promoted as though the primary result were positive.

Why these two studies do not really conflict

The studies enrolled different populations, used different schedules, and followed people for different lengths of time.

The pilot enrolled people with diagnosed mild cognitive impairment and ran for a year. The larger trial enrolled generally healthy older adults who reported memory concerns, and their baseline cognitive scores were relatively strong.

It is possible that baseline nutritional status, cognitive impairment, dose, duration, or other factors change the response. It is also possible that the positive pilot signal does not replicate.

The correct conclusion today is uncertainty—not that one study "proves" the other wrong.

Is ergothioneine a nootropic?

That label gets ahead of the evidence.

There is not yet a replicated body of randomized trials showing meaningful cognitive enhancement in healthy adults. The larger trial's primary memory endpoint is especially important because it places a boundary around the more exciting secondary findings.

Ergothioneine may eventually prove useful in a selected population. We do not know that yet.

What about anti-aging claims?

The mechanistic and observational literature is broader than the supplementation literature. That mismatch is important.

A compound can be biologically interesting, associated with healthy aging, and still fail to produce meaningful clinical benefits when supplemented. Human intervention evidence has to carry the conclusion.

At present, ergothioneine should not be described as a proven geroprotector or dementia-prevention supplement.

Safety context

The available trials reported acceptable short-term or one-year tolerability in the populations studied.[1][2] But sample sizes remain too small to characterize rare harms, and the evidence does not establish safety across pregnancy, severe organ disease, complex polypharmacy, or indefinite use.

Verdict

Ergothioneine belongs in a research database because the human literature is finally becoming testable rather than purely theoretical.

The most useful current summary is preliminary evidence with an important null primary result. That makes it scientifically interesting—and exactly the kind of compound where careful evidence grading adds more value than hype.